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DEMONSTRASI KEHADIRAN PROTEIN BERKAIT PERMUKAAN KEJUTAN 
HABA YANG ANTIGENIK DAN SPESIFIK BAGI Acinetobacter baumannii 
 
ABSTRAK 
 Acinetobacter baumannii adalah patogen nosokomial yang penting dan 
menyebabkan kadar mortaliti yang tinggi. Hal ini merupakan kebimbangan utama dalam 
kes jangkitan yang diperoleh di hospital di seluruh dunia. Sehingga kini, Acinetobacter 
baumannii telah mempamerkan peningkatan yang berterusan dalam kadar rintangan 
terhadap semua antibiotik barisan pertama. Keadaan ini menyebabkan pilihan agen 
antimikrob untuk merawat jangkitan Acinetobacter baumannii adalah terhad. Pada masa 
ini, kaedah piawai yang digunakan untuk mengenal pasti spesies Acinetobacter adalah 
hibridasi DNA-DNA, manakala dua kaedah yang disyorkan dan telah diterima secara 
meluas untuk pengenalpastian spesies Acinetobacter adalah kaedah (amplified rDNA 
restriction analysis) ARDRA dan (amplified fragment length polymorphism) ALFP. 
Walau bagaimanapun, semua kaedah tersebut terlalu rumit untuk digunakan sebagai 
ujian rutin di makmal diagnostik. Oleh yang demikian, pembangunan ujian pengesanan 
awal bagi Acinetobacter baumannii amat diperlukan untuk mengurangkan masa 
pengesanan jangkitan Acinetobacter baumannii pada pesakit. Pembangunan ujian 
diagnostik yang spesifik dan sensitif memerlukan penemuan biomarker yang tidak 
bertindakbalas silang dengan bakteria lain dan spesifik hanya untuk Acinetobacter 
baumannii. Protein kejutan haba (HSP) adalah protein yang dihasilkan oleh bakteria 
semasa berada di dalam keadaan persekitaran yang tertekan dan protein ini mempunyai 
potensi sebagai biomarker untuk digunakan dalam diagnostik. Justeru itu, tujuan kajian 
 ini adalah untuk mengesan kehadiran HSP dan biomarker daripada protein berkaitan 
permukaan (SAP) daripada Acinetobacter baumannii. Dalam kajian ini, profil SAP 
daripada strain ATCC 19606 dan strain klinikal Acinetobacter baumannii telah dipencil 
menggunakan teknik SDS-PAGE. Kajian ini menunjukkan tahap ekspresi protein SAP 
Acinetobacter baumannii berubah dengan peningkatan suhu. Profil SAP yang 
diekspreskan pada suhu 37°C telah dibandingkan dengan profil pada suhu 38.5°C dan 
41°C untuk mengenal pasti kesan perubahan suhu terhadap ekspresi SAP. Protein 
tersebut seterusnya dianalisis dengan kaedah Western blot menggunakan serum 
daripada pesakit yang dijangkiti dengan Acinetobacter baumannii serta jangkitan 
bakteria lain. Keputusan kajian menunjukkan pelbagai jalur antigen telah  dikesan 
apabila diuji dengan sera daripada pesakit yang dijangkiti dengan Acinetobacter 
baumannii (diinkubasi pada 37°C dan 41°C) terhadap antibodi kelas IgA, IgM dan IgG. 
Tindakbalas silang protein antigenik diperiksa menggunakan sera pesakit yang 
dijangkiti Enterococcus faecalis, Klebsiella pneumoniae, Pseudomonas aeruginosa, 
Salmonella spp, Staphylococcus aureus, Enterococcus faecalis dan Methicillin-resistant 
Staphylococcus aureus (MRSA). Lima protein antigenik telah dipilih untuk 
pengenalpastian dan pencirian selanjutnya menggunakan kaedah MALDI-ToF. Protein 
96.7kDa, 62.0kDa, 37.9kDa, 25.0kDa dan 16.0kDa telah dikenalpasti sebagai catalase 
HPII, Hsp60 chaperonin, phosphate ABC transporter substrate binding protein, Ycei-
like protein, and Lipopolysaccharide export system protein LptA. Peningkatan dalam 
tahap ungkapan protein-protein yang antigenic tersebut berkemungkinan menyumbang 
kepada mekanisme ketahanan bakteria tersebut pada suhu yang tinggi dalam tubuh 
pesakit, dan mempunyai potensi sebagai biomarker untuk pembangunan ujian 
diagnostik dan juga bagi pembangunan vaksin terhadap bakteria tersebut. 
 DEMONSTRATION OF ANTIGENIC AND SPECIFIC SURFACE 
ASSOCIATED HEAT SHOCK PROTEIN(S) OF Acinetobacter baumannii 
 
ABSTRACT 
Acinetobacter baumannii is an important nosocomial pathogen associated with 
high mortality. It is a major concern of hospital acquired infection (HAI) worldwide. 
Until recently, the resistance of Acinetobacter baumannii has increased steadily against 
all first-line antibiotics. Due to this situation, the choice of antimicrobial agents to treat 
Acinetobacter baumannii infections is limited. Currently, the gold standard method for 
identification of Acinetobacter species is the DNA-DNA hybridization while the two 
recommended methods that are widely accepted for identification of Acinetobacter 
species are amplified rDNA restriction analysis (ARDRA) and amplified fragment 
length polymorphism (ALFP). However, these methods are too laborious for everyday 
diagnostic use. Thus, there is a need to develop an early detection of Acinetobacter 
baumannii to reduce the time consuming in detecting the infection in patients. 
Development of a specific and sensitive diagnostic test requires discovery of 
biomarker(s) which does not cross react with other bacteria and specific only to 
Acinetobacter baumannii. Heat shock proteins (HSP) are proteins that expressed in 
bacteria during stress environment and these proteins have potential as biomarker in 
diagnostic field. Thus, the aim of this study is to detect the presence of HSPs and 
biomarker(s) in the surface associated proteins (SAPs) of Acinetobacter baumannii. The 
SAPs profile from the ATCC 19606 strain and clinical isolate of Acinetobacter 
baumannii were demonstrated using Sodium Dodecyl Sulfate-Polyacrylamide Gel 
Electrophoresis (SDS-PAGE). This study demonstrated that the expression level of 
 SAPs of Acinetobacter baumannii varies with increasing temperature. The SAPs 
profiles expressed at 37°C was compared with 38.5°C and 41°C to assess the effect of 
temperatures on the expression of the SAPs. The protein was subjected to Western blot 
using serum from patients infected with Acinetobacter baumannii as well other 
bacteremia infections. Result of this study demonstrated various antigenic bands 
detected when probed with sera from patients with Acinetobacter baumannii infections 
(incubated at 37°C and 41°C) against IgA, IgM and IgG isotypes. All the antigenic 
bands were checked for cross reaction using sera from patients infected with 
Enterococcus faecalis, Klebsiella pneumoniae, Pseudomonas aeruginosa, Salmonella 
spp, Staphylococcus aureus, Enterococcus faecalis and methicillin-resistant 
Staphylococcus aureus (MRSA). Five specific and antigenic proteins were selected for 
further identification by MALDI-ToF analysis. The protein 96.7kDa, 62.0kDa, 37.9kDa, 
25.0kDa and 16.0kDa from Acinetobacter baumannii were identified as catalase HPII, 
Hsp60 chaperonin, phosphate ABC transporter substrate binding protein, Ycei-like 
protein, and Lipopolysaccharide export system protein LptA, respectively. The 
increased expression of antigenicity level of these proteins probably is a survival 
mechanism of the bacteria at higher temperature in the host body and could be potential 
diagnostic biomarkers for diagnostic and vaccine development.  
 
 CHAPTER 1 
INTRODUCTION 
 
Over the last few decades, Acinetobacter has undergone significant taxonomic 
modification. The most important representative, Acinetobacter baumannii, has 
emerged as one of the most troublesome pathogens for nosocomial and community-
acquired infection (Gootz & Marra, 2008). According to Centres for Disease Control 
and Prevention (CDC), USA, A. baumannii is a major cause of hospital outbreaks, 
particularly in intensive care units, accounting for approximately 80% of the reported 
hospital infections (Bigot & Salcedo, 2017). Its increasing capacity to resist a broad 
range of antimicrobial agents has placed A. baumannii as a serious global health threat. 
In a hospital setting, this opportunistic pathogen is usually associated with bacteremia, 
pneumonia/ventilator-associated pneumonia (VAP), and meningitis or urinary tract 
infections. Patients that have undergone major surgery or presented with severe burns 
are at particular risk of this infection (Bigot & Salcedo, 2017). 
 
1.1 MICROBIOLOGY 
1.1.1 Historical perspective of the genus Acinetobacter 
In early 20th century, in 1911, a Dutch microbiologist’s Beijerinck has described an 
organism as Micrococcus calcoaceticus in which it has been isolated from soil and was 
enriched in a medium containing calcium-acetate mineral medium (La Riviere, 1997). 
After the following decade, the similar organism was described and assigned to at least 
15 genera and species including Diplococcus mucosus, Micrococcus calcoaceticus, 
Alcaligenes haemolysans, Mima poltmorpha, Moraxella Iwoffi, Harellea vaginicola, 
Bacterium anitratum, Morexella Iwoffi var. glucidolytica, Neisseria winogradskyi, 
Achromobacter anitratus and Achromobacter mucosus.  
 It is until 1968 the genus designation become widely accepted the comprehensive 
survey suggested by Baumann and colleagues which concluded the different species 
listed above belong to a single genus. They proposed Acinetobacter as the genus name 
(Peleg et al., 2008). 
 
1.1.2 Taxonomy 
Currently, Acinetobacter genus is characterized as strictly aerobic, non-motile, Gram-
negative, non-fermentative, oxidase-negative, catalase-positive organism (Gootz & 
Marra, 2008) and it is non-fastidious bacteria with a DNA G+C content of 39% to 47% 
(Peleg et al., 2008). To the recent taxonomic data, it was put forward that the genus 
Acinetobacter should be categorized in the new family of Moraxellaceae within the 
order Gammaproteobacteria, which includes genera of Moraxella, Acinetobacter, 
Psychrobacter and related organism (Peleg et al., 2008). After the long and complicated 
history of genus, the designation of Acinetobacter taxonomy as being distinct from 
Moraxellaceae was achieved in 1986 by Bouvet and Grimont (Peleg et al., 2008). There 
are currently 32 Acinetobacter named and un-named species. Four of the species, A. 
calcoaceticus, A. baumannii, Acinetobacter genomic species 3, and Acinetobacter 
genomic species 13TU, are referred as Acinetobacter calcoaceticus-A. baumannii 
complex (Gerner-Smidt et al., 1991; Gerner-Smidt, 1992). This is due to their 
interrelatedness and difficulties to differentiate them from each other by phenotypic 
properties. However, these group species are not primarily involved in vast majority 
clinical pathogenesis, i.e., A. baumannii, and Acinetobacter genomic species 3 and 
Acinetobacter genomic species 13TU, but also in environmental species A. 
calcoaceticus, that is usually recovered from soil and water which has not been 
implicated in serious clinical disease. Therefore, since A. calcoaceticus is an 
 environmental species, the given designation named Acinetobacter calcoaceticus- A. 
baumannii complex is not suitable in clinical context (Peleg et al., 2008). 
 
1.1.3 Natural habitats 
Genus of Acinetobacter was known as ubiquitous organism since they can be recovered 
by enrichment culture from almost environmental sample like water surface and soil. 
But, not all Acinetobacter have their natural habitats in the environment. Acinetobacter 
are part of the human skin flora and most of Acinetobacter strains that were recovered 
from human clinical specimen has at least some significant as human pathogen (Seifert 
et al., 1994). Because of the widespread presence of Acinetobacter in different 
ecological niches, there were equally misleading concept that A. baumannii is a normal 
component of the human flora. Hence, based on the basis of the ecology, epidemiology, 
and antibiotic phenotype of different isolates, (Towner, 2009) have proposed that A. 
baumannii and closely related members of the A. baumannii complex, was represented 
by strains isolated from medical environments and equipment, medical personnel, and 
hospitalized patients. In general, these isolates tend to be resistant to multiple antibiotics 
(McConnell et al., 2013). 
 
In other study, it was reported that species A. baumannii was found rarely on human 
skin 0.5% and 3% (Seifert et al., 1997; Berlau et al., 1999) and in human faeces 0.8% 
(Dijkshoorn et al., 2005). In Europe, the carrier rate of A. baumannii in the community 
is rather low. Although A. baumannii has been found in soil samples in Hong Kong and 
on vegetables in the United Kingdom, A. baumannii does not appear to be a typical 
environmental organism because there is not enough data to determine if the occurrence 
of severe community-acquired A. baumannii infections that have been observed in 
 tropical climates may be associated with an environmental source (Leung et al., 2006; 
Wang et al., 2002). A study reported that A. baumannii was occasionally found in 
infected animal (Vaneechoutte et al., 2000) and then there is speculation of the finding 
of recovered 22% of A. baumannii from body lice sample from homeless people might 
be the result of clinically silent bacteremia in these people (La Scola & Raoult, 2004).  
 
1.1.4 Growth and cultural characteristics 
Acinetobacter species of human origin grow well on solid media that are routinely used 
by clinical microbiology laboratories such as MacConkey agar and sheep blood agar 
incubated at 37°C temperature. Characteristic of the colonies on 5% sheep blood agar 
are smooth, opaque colonies, in which some isolate are β-haemolytic. Colonies on 
MacConkey agar are pinkish and the agar did not change colour which indicate the 
bacteria is non-lactose fermenting. 
 
1.2 Species identification 
1.2.1 Physiology and morphology  
Members of genus Acinetobacter are non-motile coccobacilli that are frequently 
confused with Neisseria in Gram-stained samples. They are generally encapsulated, 
obligate aerobic and do not ferment carbohydrates. Acinetobacter species are short, 
plump, Gram negative (but sometimes difficult to destain) rods, typically 1.0 to 1.5µm 
by 1.5 to 2.5µm in size during the logarithm phase of growth but often becoming more 
coccoid in the stationary phase (Bergogne-Berezin & Towner, 1996).  
 
 
 
 1.2.2 Biochemical characteristic 
A. baumannii is identified as non-motile, catalase-positive, oxidase-negative and non-
fermenting. On Triple Sugar Iron (TSI) agar, it shows alkaline slant and neutral butt and 
it does not produce gas (H2S). The phenotypic characteristics of Acinetobacter identified 
by biochemical test were shown as in Figure 1.1. 
 
 
Figure1.1 Phenotypic characteristic of Acinetobacter (Adopted from Gupta et al., 2015)  
 
1.2.3 Molecular identification  
Various genotypic methods has been developed and validated for A. baumannii 
identification to distinguish individual genomic species including tRNA spacer 
fingerprinting (Ehrenstein et al., 1996), AFLP (Janssen et al,. 1997), ARDRA 
(Dijkshoorn et al., 1998), Matrix-assisted Laser Desorption Time-of-Flight (MALDI-
ToF) technique (Marí-Almirall et al., 2017) and DNA-DNA hybridization (Visca et al., 
2011). Specific gene sequences can also be used, including the intergenic spacer (ITS) 
region between the 16S–23S rRNA genes (Chang et al., 2005), recA (Krawczyk et al., 
2002), rpoB (Gundi et al., 2009) and gyrB (Higgins et al., 2010), although not all of 
these methods successfully discriminate among members of the A. baumannii group. In 
addition, most of these methodologies are laborious, time consuming, require special 
 skills and are unsuitable for use in routine clinical identification. Among all those 
identification methods developed, DNA-DNA hybridization are the gold standard 
method for identification of Acinetobacter species while ARDRA and ALFP are the two 
recommended methods that are widely accepted for identification of Acinetobacter 
species (Yamamoto et al., 1999). 
 
According to the current taxonomy, the genus Acinetobacter includes 27 valid species 
and the most recent addition were Acinetobacter indicus (Malhotra et al., 2012) and 
nine genomic species of Acinetobacter genus identified by genomic methods DNA-
DNA hybridization, all of which encompass strains found in a wide range of ecological 
niches (McConnell et al., 2013). However, A. baumannii, genomic species 3 and 13TU, 
which were recently renamed Acinetobacter pittii and Acinetobacter nosocomialis 
respectively were the most medically relevant species belong to the A. baumannii 
complex (Nemec et al., 2011) as they are highly similar from a phenotypic point of view 
as well as by DNA-DNA hybridization (Dijkshoorn et al., 2007; Peleg et al., 2008). In 
fact, A. pittii and A. nosocomialis are often mistakenly identified as A. baumannii by 
routine commercial systems as they cannot be differentiated by currently available 
identification systems such as API and VITEK because they are so much alike (Ferreira 
et al., 2010).  
 
1.3 Clinical significant of Acinetobacter baumannii 
Acinetobacter baumannii is an important nosocomial pathogen that has been implicated 
in various infections occurs most typically in critically ill patients receiving mechanical 
ventilation in the intensive care units. Studies and a systematic reviews have reported 
that nosocomial infections with A. baumannii is associated with increased in mortality 
 rates (Falagas et al., 2006; Abbo et al., 2007; Falagas & Rafailidis, 2007; 
Lee et al., 2007), while community-acquired pneumonia caused by A. baumannii much 
less frequent than nosocomial infection (Anstey et al., 1992, 2002; Chen et al., 2001; 
Leung et al., 2006). 
Hospital-acquired infections (HAIs) caused by A. baumannii include bloodstream 
infections, VAP, skin and soft-tissue infections, wound infections, respiratory and 
urinary tract infections, endocarditis, secondary meningitis and others related diseases 
(Lee et al., 2008). The most frequent clinical manifestations of nosocomial A. 
baumannii infection were VAP and bloodstream infections (Seifert et al., 1995; 
Cisneros et al., 2002; Wisplinghoff et al., 2004). It was said that VAP with mortality 
rate reported to be between 40% and 70% (Fagon et al., 1996; Garnacho et al., 2003), 
were caused by colonization of A. baumannii from the airway via environmental 
exposure, and it was followed by the development of pneumonia in the patients 
(Dijkshoorn et al., 2007). While the most common sources of A. baumannii bloodstream 
infections were lower respiratory tract infections and intravascular devices (Seifert et 
al., 1995; Cisneros et al., 1996; Jang et al., 2009; Jung et al., 2010) and it was reported 
that the mortality rates for A. baumannii bloodstream infections to be between 28% and 
43% (Seifert et al., 1995; Wisplinghoff et al., 2004). Risk factors associated with 
acquiring A. baumannii bloodstream infections include immunosuppression, ventilator 
use associated with respiratory failure, previous antibiotic therapy, colonization with 
A. baumannii, and invasive procedures (Jang et al., 2009; Jung et al., 2010).  
A. baumannii has also emerged as an important cause of burn infection in military 
personnel as evidenced by a recent report characterizing bacterial infections in a military 
burn unit which identified A. baumannii as the most common cause of burn site 
 infection with 53% of isolates demonstrating multidrug resistance (Keen et al., 2010). 
Burn infection can be especially problematic as it can delay wound healing and lead to 
failure of skin grafts, and wound site colonization can progress to infection of the 
underlying tissue and subsequent systemic spread of the bacteria (Trottier et al., 2007). 
A. baumannii is an increasingly important cause of meningitis, with the majority of 
cases occurring in patients recovering from neurosurgical procedures 
(Cascio et al., 2010) although there were rare cases of A. baumannii meningitis have 
been reported (Ozaki et al., 2009). Clinical features of A. baumannii meningitis are 
consistent with those of bacterial meningitis caused by other organisms and include 
fever, altered consciousness, headache, and seizure (Rodríguez Guardado et al., 2008). 
Mortality rates associated with A. baumannii meningitis are difficult to estimate because 
of a limited number of studies with adequately sized study populations. As with other 
types of infections caused by this pathogen, the emergence of drug resistance has posed 
an increasing challenge to clinicians (Wareham et al., 2008). 
 
1.3.1 Pathogenesis and immune responses 
Acinetobacter baumannii were able to withstand desiccation and disinfection to persist 
in the hospital environment. This ability contributes to the strength of A. baumannii 
tendency to form biofilms on a number of abiotic surfaces, including catheters, 
ventilators, and other medical devices, enhancing bacterial transmission (Pour et 
al., 2011). The immune responses were mainly dependent on how the host interacts with 
pathogen. A. baumannii is a versatile pathogen that can adhere to and invade numerous 
cell types, yet different cell types display varying degrees of susceptibility to invasion 
(Choi et al., 2008). 
 
 It was reported that the invasion of A. baumannii into vertebrates host does not go 
undetected due to the vigilant monitoring by rapid immune response as the recognition 
by sentinel receptors triggers the immune response. The innate immune receptor on the 
host cells will detect the bacterial pathogen-associated molecular patterns (PAMPs) that 
will give intracellular signalling pathways that promote transcription, processing and 
secretion of inflammatory mediators which will response to stimulates chemokine 
secretion and subsequent recruitment of immune cells to the site of infection in both 
pneumonia and septicaemia infection. Although there are multiple inflammatory 
signalling cascades leading to cytokine and chemokine secretion, A. baumannii PAMPs 
are known to activate the NF-κB and MAPK pathways (March et al., 2010). This 
process will induces the release of numerous chemokines, including macrophage 
inflammatory protein 2 (MIP-2), monocyte chemoattractant protein (MCP-1), and 
keratinocyte-derived chemokine (KC)/IL-8, and pro-inflammatory cytokines such as 
TNF-α, IL-1β, and IL-6 (Knapp et al., 2006; van Faassen et al., 2007). Natural killer 
cells participate in neutrophil recruitment through increased expression of KC/IL-8 
(Tsuchiya et al., 2012). Lymphocytes and granulocytes produce a number of 
antimicrobial factors in response to infection and killing of A. baumannii, including 
defensins, cathelicidins, reactive oxygen species (ROS), and reactive nitrogen species 
(RNS) (Qiu et al., 2009; March et al., 2010). 
 
Garcia et al has reported that the lipopolysaccharide (LPS) of A. baumannii is highly 
immunostimulatory (Garcia et al., 1999). Of the three components of LPS (lipid A, core 
polysaccharide, and O-antigen), lipid A is the main immune-activating portion of the 
molecule. Remarkably, several colistin-resistant mutants of A.baumannii have been 
described with mutations in lipid A biosynthetic genes that eliminate LPS expression 
 and increase membrane permeability (Moffatt et al., 2010). Finally, the loss of the 
glycosyltransferase lpsB truncates LPS at the core polysaccharide and revealed that full 
length LPS were necessary for serum resistance and survival in vivo (Luke et al., 2010). 
 
During the invasion, A. baumannii will attaches to bronchial epithelial cells (Lee et al., 
2008) and following  the attachment, A. baumannii will invade epithelial cells in a 
microfilament and microtubule-dependent, zipper-like mechanism (Choi et al., 2008). 
This interaction will lead to host cell cytotoxicity that specifically, during infection host 
epithelial cells up regulate the caspase-3, -8, -9, and poly[ADP-ribose] polymerase that 
correlate with secretion of cytochrome C and apoptosis-inducing factor from the 
mitochondria (Choi et al., 2005). The stimuli and signalling pathways implicated in cell 
death are not established; however, they involve imbalanced calcium homeostasis, pro-
inflammatory cytokines, and oxidative stress (Smani et al., 2011). 
 
1.3.2 Virulence factors 
A. baumannii has a remarkable capacity to survive in unfavourable conditions in 
virulence mechanisms. This molecular feature promotes environmental persistence; 
including desiccation resistance, biofilm formation and motility, secretion systems, 
surface glycoconjugates and micronutrient acquisition systems that facilitate A. 
baumannii pathogenesis (Harding et al., 2018). A study reported that two attributes, 
drug resistance and environmental persistence, have enabled A. baumannii to thrive in 
the nosocomial environment (Roca et al., 2012). 
 
A. baumannii has the resistancy mechanisms to commonly health-care environments 
(disinfection, desiccation and oxidative stress) which is similar to antibiotic resistance, 
 A. baumannii has adapted to those stress (Wong et al., 2017). In desiccation resistance, 
some of A. baumannii clinical isolates are able to maintain viability under dry 
conditions for almost 100 days (Antunes et al., 2011; Giannoul et al., 2013). The ability 
of A. baumannii to maintain viable under conditions of water limitations is with the 
help of polysaccharides that are composed of repeating carbohydrate units and 
function as a glycan shield that encompasses the entire bacterium and protects it from 
external threats (Scott et al., 2014). The capsular polysaccharide covering A. 
baumannii cells that are grown in a biofilm under dry conditions were likely 
contributes to the resistance to desiccation in A. baumannii (Espinal et al., 2012). 
Moreover, a study has proposed a relation between the desiccation resistances with 
the composition of the outer membrane bacteria proteins (Boll et al., 2015). There 
was also a study on the outer membrane protein A (OmpA) which suggested that A. 
baumannii OmpA contributed to the virulence of the bacteria, in which A. baumannii 
OmpA mutants were shown to be deficient in inducing apoptosis in a human 
laryngeal epithelial cell line (Choi et al., 2005). The OmpA that localized in the 
mitochondria will induce apoptosis through the release of the pro-apoptotic molecules 
cytochrome C and apoptosis-inducing factor, in which might be the pathway of 
A. baumannii inducing the damage to human airway cells during infection. The OmpA 
protein also plays a role in adherence and invasion of epithelial cells that may contribute 
to the dissemination of A. baumannii during infection (Choi et al., 2008). The OmpA 
protein also contributes to the ability of A. baumannii to persist and grow in human 
serum as it has been shown that OmpA interacted with soluble inhibitors of the 
alternative complement pathway and allows the bacteria to avoid complement-
mediated killing (Kim et al., 2009). However, OmpA is unlikely to be the only factor 
that contributes to serum resistance as different A. baumannii strains, all of which 
 contain putative OmpA genes, have significantly different capacities for growth and 
survival in human serum (Antunes et al., 2011).  
 
Moreover, during periods of desiccation, oxidative stress was also induced. As a 
result, A. baumannii will upregulated proteins that were associated with detoxifying 
reactive oxygen species (Gayoso et al., 2013). Some strain of Acinetobacter  are 
believed to have the highest tolerance to hydrogen peroxide such as strain  A. 
gyllenbergii which were able to withstand 100 mM hydrogen peroxide with no loss in 
viability and maintains viability even in 320mM hydrogen peroxide (Derecho et al., 
2014). As A. gyllenbergii has been isolated from human specimens, it is likely that 
more clinically relevant strain such as A. baumannii will be more tolerant towards 
oxidative stressors given (Nemec et al., 2009). In fact, in response to oxidative stress, 
the emergence of A. baumannii strains that contain the insertion sequence element 
ISAba1 upstream of the catalase gene, katG, has been reported, which drives the 
expression of katG and enhances resistance to high levels of hydrogen peroxide 
(Wright et al., 2017). In hospitals and other health-care settings, disinfectants such as 
chlorhexidine, are extensively used. These antiseptics are effective against Gram-
negative and Gram-positive bacteria which disrupts the cell membranes. But, A. 
baumannii has been shown to actively pump chlorhexidine out of the cell using the 
Acinetobacter chlorhexidine (AceI) efflux protein, thus possibly promoting survival of 
the bacteria under stressful conditions (Hassan et al., 2013). There were also other 
disinfectant which is ethanol that has shown to promote the growth and virulence of A. 
baumannii in low concentrations (Nwugo et al., 2012). 
Biofilms are encased in an extracellular matrix which likely to have an important role 
in the interactions of A. baumannii with its host and it is also contributes to medical-
 device-associated infections. Thompson et al reported that during skin and soft-tissue 
infections, A. baumannii populations form robust biofilms (Thompson et al., 2014). It 
was also reported that A. baumannii also forms biofilm communities on most abiotic 
surfaces, including health-care-associated equipment, such as endotracheal tubes, 
polycarbonate and stainless steel (Greene et al., 2016a). Greene et al also reported 
that bacteria within biofilm communities, including A. baumannii, have increased 
tolerance to extracellular stresses
 
(Greene et al., 2016b).  
 
1.3.3 Risk factors 
Acinetobacter baumannii is an important nosocomial infection in many hospitals, which 
is difficult to control and treat because of its prolonged environmental survival and its 
ability to develop resistance to multiple antimicrobial agents (Tseng et al., 2007). A. 
baumannii appear to be an extremely rapid antimicrobial resistance and these 
resistances are multiple which cause serious therapeutic problems (Cisneros et al., 
2002). There are several studies that have been conducted to find the risk factor for 
bacteraemia caused by multi-drug resistant A. baumannii which lead to higher mortality 
and medical cost compared with non-Multidrug resistance A. baumannii bacteraemia. 
This risk factor might be different between areas with endemic colonization and 
epidemic outbreak of infection (Shih et al., 2008). From the previous studies of risk 
factors, it was found that ICU admission, surgical operation, total parental nutrition, 
invasive procedures such as central nervous catheter, endotracheal tube, urinary 
catheter, or nasogastric tube, previous administration of carbapenems and previous 
exposure to broad-spectrum antibiotics have been identified as risk factors for 
acquisition of A. baumannii (Garcia-Garmendia et al., 2001, Baran et al., 2008). The 
risk factors that affect individual to A. baumannii were similar to those that have been 
 identified for other multi-drug resistance organisms. Risk factors that are specific for a 
particular setting have also been identified, such as the hydrotherapy that was used to 
treat burn patients and the pulsatile lavage treatment that was used for wound treatment 
(Maragakis et al., 2004). The most frequent clinical manifestations of nosocomial A. 
baumannii are ventilator-associated pneumonia and bloodstream infection which both 
are associated with considerable morbidity and mortality (Seifert et al., 1995; Cisneros 
et al., 2002). 
 
1.3.4 Prevalence 
The prevalence of nosocomial bloodstream infections due to A. baumannii currently has 
become public health concern in many countries, which contributed from 2% to 10% of 
all Gram-negative bacterial infections in Europe (Hanberger et al., 1999) and accounted 
for about 2.5% cases in the United State (Jones et al., 2004). The National Nosocomial 
Infection Survey data for the US intensive care units indicated that the Acinetobacter 
species caused 6.9% of hospital-acquired pneumonia in 2003, compared with 1.4% in 
1975. The rates of bloodstream infection, surgical site infection, and urinary tract 
infection have also been increased during this period (Weinstein et al., 2005).  
 
It is reported that between 2% and 77% of all Acinetobacter clinical isolate species in 
Asian countries were resistant to imipenem and it was highly prevalent particularly in 
Thailand and India (Lagamayo, 2008). In Thailand, Acinetobacter species caused 44% 
or 69% of cases of nosocomial pneumonia cases in ICU neonates, and it is reported that 
69% of ICU patients with device-associated nosocomial infections was due to infection 
by ceftazidime-resistant A baumannii. Besides, the susceptibility of A. baumannii to 
amikacin was reported to be low, while netilmicin and cefoperazone/sulbactam are the 
 preferred treatments. In India, Acinetobacter species have been found to be high 
resistance to most antibacterial agents among ICUs patients (Singh et al., 2002). MDR 
Acinetobacter species are very common in India, and it is reported that the use of 
colistin are many in routine Indian hospitals (Garnacho, 2003). In Korea, 7.4% of all 
Acinetobacter species isolates were resistant to all antimicrobial agents except 
cefoperazone-sulbactam (15%) and imipenem (13%) and the study described that 
Acinetobacter isolates from sputum were non-susceptible to imipenem (Lee, 2004). In 
China, a study in 2004 reported that all A. baumannii isolates were resistant to multiple 
antibiotics including meropenem. In that study, 72% to 78% were resistant to the third-
generation and fourth-generation cephalosporins (Johnson et al., 1999). While in 
Singapore, data presented by the researchers indicated that among Acinetobacter 
species, approximately 50% were susceptible to aminoglycosides, yet only 
approximately 20% were susceptible to carbapenems (Kuah et al., 1994). The study 
reported that the overall rate of drug resistance in Acinetobacter species was 84%, 
whereas that in VAP cases was reported to be 60% to 70%. In Vietnam, it was reported 
that the most frequent pneumonia associated to hospital acquired infections (HAIs) was 
due to A. baumannii (Phu et al., 2016). In Malaysia, there is a study on the A. baumannii 
isolated from the intensive care unit (ICU) of a local teaching hospital in Kuala Lumpur 
from year 2006 to 2009 (Kong et al., 2011). The resistance rate shown by A. baumannii 
to amikacin was decreased from 70.5% in 2006 to 52.0% in 2007 and it was reported 
increased in prevalence to 91.5% and 97.3% in 2008 and 2009 respectively. The 
resistance to gentamicin decreased from 91.8% in 2006 to 78.7% in 2008, however, the 
resistance increased slightly to 83.8% in 2009. Similarly, resistance to 
trimethoprim/sulfamethoxazole decreased to 88.0% in 2007 and 76.6% in 2008 
compared to 98.4% in 2006, then increased slightly to 89.2% in 2009. The clinical 
 isolates had a high rate of resistance to ampicillin/sulbactam throughout the 4-year 
period (82.0% in 2006, 88.0% in 2007, 78.7% in 2008, and 94.6% in 2009). Although 
no cefoperazone/sulbactam-resistance isolates were observed in 2006, resistance was 
detected in 2007 (40.0%), and the resistance rates increased to 55.3% in 2008 and 
62.2% in 2009. All the clinical and environmental isolates of A. baumannii were 
susceptible to polymyxin B.  
 
1.3.5 Antimicrobial susceptibility and resistant mechanisms 
Considered susceptible to major antimicrobial drug classes in the 1970s, the clinical 
importance of the Gram-negative, nosocomial pathogen A.baumannii has increased 
steadily and today this organism is displaying resistance against all first-line antibiotics 
(Peleg et al., 2008).  A. baumannii is attracting much attention owing to the increased 
antimicrobial resistance and occurrence of the strain that are resistant to virtually all 
available drugs (Perez et al., 2007). This organism is generally intrinsically resistant to a 
number of commonly used antibiotics including aminopenicillins, first and second 
generation cephalosporins and chloramphenicols (Vila et al., 1993; Seifert et al., 1995). 
It also has remarkable capacity to acquire mechanisms that confer resistance to broad-
spectrum beta-lactams, aminoglycosides, fluoroquinolones and tetracyclines. A 
baumannii exhibited a remarkable ability to rapidly develop antibiotic resistance that led 
to multidrug resistance within a few decades (Bergogne Berezin et al., 1996).  
 
Some strains of A. baumannii have become resistant to almost all currently available 
antibacterial agents (Looveren,2004; Perez et al.,2007) and mostly through acquisition 
of plasmid (Joshi et al., 2003), transposon (Smith et al., 2003), or integrons carrying 
cluster of genes encoding resistance to several antibiotic families (Segal et al., 2003; 
 Poirel et al., 2003). A recent study reported that 58%, 38.7% and 35% of Acinetobacter 
isolates showed resistance to piperacillin-tazobactam, tigecycline and imipenem 
respectively, and approximately 95% of Acinetobacter isolates were MDR, while 12.9% 
were extended-spectrum β-lactamases (ESBL)-producer (Mishra et al., 2013). 
 
Many studies have suggested the increase trend in A. baumannii resistance to majority 
of the antimicrobial agents. However, because of the scarcity of large-scale surveillance 
studies and the difficulties in comparing local reports, such trends are difficult to 
quantify on a global level. Resistance rates can vary according to the country and the 
individual hospital and depends on biological, epidemiological or methodological 
factors (Wisplinghoff et al., 2007). It is reported that majority of isolates from the 
antimicrobial agent tested with one hundred and twenty four A. baumannii isolate were 
determined to be resistant to imipenem (96.9%) in Italy, resistant to colistin were 
(47.7%)  and 34 isolates were susceptible, with an MIC50 of 2 mg/L and MIC90 of 
256 mg/L, isolate from Greece resistance colistin (56.8%) while resistant to tigecycline, 
five isolates exhibited a resistant phenotype (7.7%), 23 were intermediate (35.4%) and 
37 isolates (56.9%) were considered susceptible (Nowak et al., 2017). The resistance of 
A. baumannii to antimicrobial agents is mediated by all of the major resistance 
mechanism that are known to occur in bacteria, including modification of target sites, 
enzymatic inactivation, active efflux and decreased influx of drug (Poirel et al., 2003). 
Beta-lactamase are the most diverse group of enzyme that are associated with resistance, 
and more than 50 different enzyme, or their allelic forms have been identified so far in 
A. baumannii (Dijkshoorn et al., 2007). In previous study, aac(6´)-Ib and aac(6´)-Ih 
have been identified as the most prevalent plasmid mediated aac(6´)-I genes among A. 
baumannii strain through which aminoglycoside resistance can be attributed to at least 
 nine distinct modifying enzymes with different combination in some strain (Doi et al., 
2004). Another study reported that resistance to tetracyclines has been associated with 
tet(A) and tet(B) genes that encode tetracycline-specific efflux pump (Huy et al., 2005). 
ISAbal was also thought to have a key role in some carbapenem-resistant strains by 
enhancing the expression of intrinsic OXA-51-like carbapenemases (Turton et al., 
2006). Another chromosomal system that is typically found in A. baumannii is the 
AdeABC efflux system (Magnet et al., 2001). Reduced susceptibility to carbapenemases 
has also been associated with the modification of penicillin-binding proteins and porins 
or with up-regulation of the AdeABC efflux system, which might in high-level 
carbapenems resistance in A. baumannii (Bou et al., 2000). Another study showed that 
production of β-lactamase and reduced expressions of PBP 2 (penicillin-binding protein 
biotype 2) are the most frequently observed mechanism of resistance to carbapenems 
(Fernandez-Cenca et al., 2003).  
 
Recently, carbapenem resistance A. baumannii isolates in southern Europe which is 
recovered from patients with VAP were almost universal. Alarmingly, 32% of isolates 
were multi-drug resistant, 34% were extensively-drug resistant and 31% were pan-drug 
resistant. From the study also, Rep-PCR has revealed that IC2 as the predominant 
lineage with 82% of isolates grouping in one large cluster which consisted majority of 
the PDR isolates. This result suggesting the presence of an epidemic pan-drug 
resistant A. baumannii clone has spread within Greece, Italy and Spain (Nowak, 2017). 
 
 1.3.6 Treatment  
According to the Infectious Disease Society of America (IDSA), A. baumannii is 
considered as one of the three increasingly problematic Gram-negative pathogens 
(Daniels, 2008). MDRAB infections are difficult and costly to treat. A study at a public 
teaching hospital found that the mean total hospital cost of patients who acquired 
MDRAB was higher than that of control patients who had identical burn severity of 
illness (Wilson et al., 2004). 
 
Treatment of Acinetobacter infection has been complicated by increasing resistance due 
to aminoglycoside-modifying enzymes, ESBLs, carbapenemases or changes in outer 
membrane proteins and penicillin-binding protein (Levin et al., 2002). Many isolates are 
now resistant to all aminoglycosides, cephalosporins and fluoroquinolones (Landman et 
al., 2002). The carbapenems and combination of β-lactam with β-lactamase inhibitor, 
such as ampicillin-sulbactam, retain useful activity but resistant rates are increasing 
(Quale et al., 2003). Talbot, (2008) had showed that the carbapenems which have been 
demonstrated to have greatest inherent activity against A. baumannii have increase in 
resistant frequency from 9% to 39%. While the rate of resistant to fluoroquinolones 
increased from 50% to 70%. For β-lactam antibiotics, it is increased in resistant from 
39% to 66%. All these changes in the epidemiology and resistant rates of A. baumannii 
have led clinicians to adopt therapeutic options, such as colistimethanate sodium 
(colistin which is also known as polymixin E),  the used of which had previously been 
abandoned in clinical use because of an unacceptable high rate of renal toxicity (Falagas 
et al., 2005; Li et al., 2006). But, recently, there were some reports of the use of colistin 
in some pan-drug resistance strain (Roca et al., 2012).  
 
 Several studies have tested in vitro activity of tigecycline, a semi-synthetic tetracycline 
(glycycline) against A. baumannii and it is reported as good bacteriostatic tetracycline 
(Curcio et al., 2008). However, there is some doubt in the role of tigecycline in treating 
MDRAB infection (Ruzin et al., 2007). The ability of Acinetobacter to rapidly acquire 
resistance to this glycycline antimicrobial adds further stimulus for the discovery of 
newer antimicrobial with activity against this problematic organism (Peleg et al., 2007). 
Bloodstream infection with A. baumannii are occurs with increasing frequency which 
resulting in significant morbidity and mortality with ranging from 8% to 43% (Scheetz 
et al., 2007). Thus, clinicians must resort to empirical combination therapy which has an 
unproven utility where therapeutic failure and relapse is anticipated. A study also have 
been reported that BAl 30376 (Basilea Pharmaceutica Ltd, Switzerland), a novel β-
lactam/β-lactamase inhibitor combination represent an interesting potential approach for 
MDRAB therapy (Daniel, 2008). However, there is no clinical study has been reported 
on this therapy. 
 
1.4 The importance of heat shock proteins (HSPs) 
Heat-shock proteins (HSPs), or stress proteins, are highly conserved and present in all 
cells in organisms. Heat shock proteins are present in cells under normal conditions, but 
are expressed at high levels when exposed to a sudden temperature jump or other 
stresses (Guimarae et al., 2009). The heat-shock response is the mechanism by which 
cells react to increases in temperature to prevent damage, and it involves the expression 
of the almost universally conserved heat-shock genes (Gomes & Simao, 2009). High 
temperatures and other stresses, such as altered pH and oxygen deprivation, make it 
more difficult for proteins to form their proper structures and caused some already 
structured proteins to unfold (Martin et al., 1992), left uncorrected and misfolded 
 proteins form aggregates that may eventually kill the cell.  Heat shock proteins are 
induced rapidly at high levels to deal with this problem.  Nishikawa et al., (2005) 
reported that in the case of endoplasmic reticulum associated protein degradation C 
(ERAD-C), degradation is typically dependent on a specific subset of cytosolic 
chaperones which include Hsp70 and Hsp40 members and this report suggests that these 
proteins may be directly responsible for recognizing misfolded cytosolic domains of 
transmembrane proteins. Most heat shock proteins are molecular chaperones.  Selected 
HSPs, also known as chaperones, play crucial roles in folding and unfolding of proteins, 
assembly of multiprotein complexes, transport and sorting of proteins into correct 
subcellular compartments, cell-cycle control and signalling, and protection of cells 
against stress or apoptosis (Martin et al., 1992). Few studies have suggested the role of 
HSPs in the bacterial stress response caused by antibiotics. Yamaguchi et al., (2003) 
demonstrated that the chaperones DnaK and GroEL have an effect on the antimicrobial 
activity of the fluoroquinolone levofloxacin in E. coli. According to this study, these 
chaperones might contribute to quinolone resistance because they sequester the 
aggregates that accumulate in cells exposed to fluoroquinolones (Guimaraes et al., 
2009). Studies have reported that the Hsp70 might inhibit extrinsic and intrinsic 
pathways of apoptosis by protecting certain proteins such as the oncoproteins Raf-1 and 
Akt-1, from degradation during elevated temperatures (Davenport et al., 2010; 
Williamson et al., 2009). Another Hsp70 mechanism was reported to be involved in the 
cell survival by suppressing the RIP1/3 amyloid formation (Bukau et al., 2006). While 
another study reported that the Hsp90 are well known to release proteins from 
chaperone, leading to protein degradation and, ultimately, apoptotic cell death (Matts et 
al., 2011; Whitesell &, Lindquist, 2005).  
 
 1.5 Rationale of the study 
The evolution of antimicrobial resistance to multiple antibiotics leads to urgency in 
developing rapid method for identification of the A. baumannii in order to limit and 
control the outbreak before it can causes serious therapeutics problems. Quick 
identification of the pathogen in clinical specimens is important to guarantee suitability 
of clinical treatment and management of the patients. It is also a major difficulty to 
control the emergence of multidrug-resistance characteristics to the commonly 
prescribed antibiotics adding the challenge to the treatment of the disease. Multidrug-
resistance A. baumannii is highly affecting the increase in medical cost, extending time 
of hospitalization and also shorten life time of patients.  
Currently, conventional culture and biochemical methods are being used to detect this 
organism in majority of clinical medical laboratories. Even though these methods have 
giving good results, it is time consuming and too laborious for routine diagnostic use. 
Due to this situation, there is a need in developing an alternative diagnostic method for 
the early identification of this pathogen in infected patients. The identification of the 
pathogen at early stage is crucial in order to control the disease outbreak caused by A. 
baumannii and to prevent further complication in infected patients as it has been 
associated with high mortalities (Nhu et al., 2014).  
 
A study reported that the ability of A. baumannii to adapt and to survive in a range of 
environments has been a key factor for its persistence and success as an opportunistic 
pathogen (De Silva et al., 2018). As such, HSPs that expressed during high temperatures 
may have roles in the bacteria to regulate the expression of virulence related proteins. 
Moreover, the immunogenic properties of HSPs have been widely reported in infectious 
diseases. Various studies have proven the capability of HSPs as protective vaccines 
 candidates against bacterial infection (Lee et al., 2006; Wilhem et al., 2005). To date, 
there is no commercially available kit to detect A. baumannii infection. Hence, the 
antigenic HSP can be a potential biomarker candidate for early detection of this 
infection. As such, the aim of this study is to identify the presence of HSPs and 
biomarker(s) in the SAPs of A. baumannii. These proteins can be used to develop rapid 
and reliable protein-based diagnostic tests for the identification of A. baumannii which 
would significantly improve effective management of this infection. 
 1.6 Objective of the study 
Main objective of the study: 
To demonstrate presence of specific heat shock protein which is antigenic and specific 
for Acinetobacter baumannii 
Specific objectives of this study are as follow: 
1. To study the surface associated protein (SAP) profiles of Acinetobacter 
baumannii expressed at 37˚C, 38.5˚C and 41˚C by sodium dodecyl sulphate 
polyacrylamide gel electrophoresis (SDS-PAGE) 
2. To study the immunogenic profile of the SAPs against IgA, IgM and IgG 
express at 37˚C and 41˚C  by Western blot technique 
3. To characterize the SAPs of A. baumannii that is highly antigenic and 
specific using mass spectrophotometry. 
 
 
 1.7 Flow chart of the study 
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